elinogrel

Elinogrel is a small molecule, direct, competitive, and reversible inhibitor of the platelet P2Y12 receptor. It was developed as an antiplatelet agent for both intravenous and oral administration. Unlike clopidogrel, elinogrel is not a prodrug and does not require metabolic activation; it acts rapidly with effects lasting about 12 hours. Elinogrel impairs ADP-mediated activation of the glycoprotein GPIIb/IIIa complex on platelets, thereby inhibiting platelet aggregation—a key step in thrombosis. The drug was originally developed by Portola Pharmaceuticals and later licensed to Novartis for further development. Clinical trials focused on acute coronary syndrome, myocardial infarction, and prevention of secondary thrombotic events; however, development was terminated in 2012 before reaching Phase III due to strategic reasons[1][2][5][6][7].

Other names

elinogrel potassium